Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate

Journal of the American Society of Nephrology

Volumn 26, Issue 5, 2015, Pages 1150-1160

  Xie, Jian ^a   Yoon, Joonho ^a   An, Sung Wan ^a   Kuro o, Makoto ^b,c,d   Huang, Chou Long ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UREA; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE TARGETING; HEART VENTRICLE HYPERTROPHY; HEMATOCRIT; HISTOLOGY; MOUSE; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DOMAIN; RISK FACTOR; SOLUBILITY; TRANSGENE; UREA NITROGEN BLOOD LEVEL; UREMIA; UREMIC CARDIOMYOPATHY; WILD TYPE MOUSE; ANIMAL; BLOOD; CARDIOMYOPATHIES; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE MODEL; FIBROSIS; HEART MUSCLE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; FIBROSIS; GLUCURONIDASE; MALE; MICE; MYOCARDIUM; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TRPC CATION CHANNELS;

EID: 84929353472     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014040325     Document Type: Article

References (46)

1. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
2. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833, 2005
3. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565: 143-147, 2004
4. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG: The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310: 490-493, 2005
5. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang C-L: Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A 105: 9805-9810, 2008
6. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW: Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24: 3438-3450, 2010
7. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, Schimel D, Kuo CJ, Gutkind JS, Hwang PM, Finkel T: Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317: 803-806, 2007
8. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006
9. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006
10. ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000
11. Razzaque MS: The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5: 611-619, 2009
12. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
13. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, Takeshige K, Kamiya T: The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131: 3182-3188, 2001
14. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
16. Taddei S, Nami R, Bruno RM, Quatrini I, Nuti R: Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev 16: 615-620, 2011
17. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4[Suppl 1]: S79-S91, 2009
18. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia - beyond coronary heart disease. Semin Dial 21: 308-318, 2008
19. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
20. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
21. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
22. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747, 2012
23. Kuro-o M: Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 9: 650-660, 2013
24. Kalra SS, Shanahan CM: Vascular calcification and hypertension: Cause and effect. Ann Med 44[Suppl 1]: S85-S92, 2012
25. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
26. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
27. Hu MC, Kuro-o M, Moe OW: The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 27: 2650-2657, 2012
28. Xie J, Cha S-K, An S-W, Kuro-O M, Birnbaumer L, Huang C-L: Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 3: 1238, 2012
29. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y: Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015-1020, 2001
30. Hamada K, Taniguchi Y, Shimamura Y, Inoue K, Ogata K, Ishihara M, Horino T, Fujimoto S, Ohguro T, Yoshimoto Y, Ikebe M, Yuasa K, Hoshino E, Iiyama T, Ichihara A, Terada Y: Serum level of soluble (pro) renin receptor is modulated in chronic kidney disease. Clin Exp Nephrol 17: 848-856, 2013
31. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22: 124-136, 2011
32. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH, Vervloet MG; NIGRAM Consortium: Laboratory aspects of circulating α-Klotho. Nephrol Dial Transplant 28: 2283-2287, 2013
33. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN: TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 116: 3114-3126, 2006
34. Rowell J, Koitabashi N, Kass DA: TRP-ing up heart and vessels: Canonical transient receptor potential channels and cardiovascular disease. J Cardiovasc Transl Res 3: 516-524, 2010
35. Frey N, Katus HA, Olson EN, Hill JA: Hypertrophy of the heart: A new therapeutic target? Circulation 109: 1580-1589, 2004
36. Vega RB, Bassel-Duby R, Olson EN: Control of cardiac growth and function by calcineurin signaling. J Biol Chem 278: 36981-36984, 2003
37. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H: Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res 111: 1470-1483, 2012
38. Semple D, Smith K, Bhandari S, Seymour AM: Uremic cardiomyopathy and insulin resistance: A critical role for akt? J Am Soc Nephrol 22: 207-215, 2011
39. Yoshida T, Fujimori T, Nabeshima Y: Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1α-hydroxylase gene. Endocrinology 143: 683-689, 2002
40. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y: alpha-Klotho as a regulator of calcium homeostasis. Science 316: 1615-1618, 2007
41. Agarwal I, Ide N, Ix JH, Kestenbaum B, Lanske B, Schiller NB, Whooley MA, Mukamal KJ: Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 3: e000584, 2014
42. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122: 2543-2553, 2012
43. Moe OW: Fibroblast growth factor 23: Friend or foe in uremia? J Clin Invest 122: 2354-2356, 2012
44. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI: Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 294: F450-F454, 2008
45. Liu Z, Xie J, Wu T, Truong T, Auchus RJ, Huang CL: Downregulation of NCC and NKCC2 cotransporters by kidney-specific WNK1 revealed by gene disruption and transgenic mouse models. Hum Mol Genet 20: 855-866, 2011
46. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y: Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol 24: 771-785, 2013